Comparing esketamine, crisis planning, and usual care to prevent suicide
Part of Mental health clinical trials.
This study compares three approaches to help prevent suicide: a new medication called esketamine (a nasal spray), crisis response planning (a personalized safety plan), and enhanced usual care. It aims to see which approach is more effective in reducing suicidal thoughts and behaviors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 years old or older.
- You went to a participating public emergency service in Indaiatuba, Brazil.
- You attempted suicide in the last 30 days, or you currently have serious suicidal thoughts with intent to act (with or without a plan).
- You live in the Indaiatuba area and can attend follow-up visits.
- You are not being admitted to a psychiatric inpatient unit right now.
- You do not have medical conditions that prevent safe use of esketamine, are not pregnant or breastfeeding, and do not have a severe mental health condition like schizophrenia or acute psychosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether ketamine plus a structured crisis-response plan can help reduce suicidal thoughts for adults admitted from the ER. It also aims to make care in the emergency setting more consistent and effective.
This study tests combining a specific type of therapy (BCBT-SP) with esketamine nasal spray to help people with treatment-resistant depression who are having ongoing suicidal thoughts. The goal is to see if this combination can reduce suicidal ideation more effectively than either treatment alone.
This Phase 3 study tests ketamine to reduce ongoing suicidal thoughts and help prevent another suicide attempt in youth after a recent attempt. It will compare ketamine treatment against standard care to see if it helps improve safety and reduce suicide risk.
This trial tests if esketamine (a nasal spray) can quickly reduce symptoms of major depression and suicidal thoughts in teenagers who need urgent hospital care.
This study tests whether a single dose of ketamine, given by injection in the emergency department, combined with brief psychotherapy, can quickly reduce suicidal thoughts and keep you safe. It aims to find fast-acting relief for people in crisis, possibly helping you feel better sooner and reducing the risk of future attempts.
This trial compares two treatments—ECT (electroconvulsive therapy, which uses electrical stimulation) and ketamine (a medicine given as a shot)—to see which works better for quickly reducing suicidal depression. It is for adults who are in a severe depressive episode with active suicidal thoughts.
Hear when a new Suicide Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.